Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

PHASE2/PHASE3TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Cigarette SmokingNicotine Dependence
Interventions
DRUG

varenicline (Chantix)

For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.

DRUG

bupropion (Zyban)

After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.

DRUG

nicotine patches

21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.

Trial Locations (2)

27609

Duke Center for Smoking Cessation, Raleigh

27705

Duke Center forSmoking Cessation, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Philip Morris USA, Inc.

INDUSTRY

lead

Duke University

OTHER

NCT01560507 - Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants | Biotech Hunter | Biotech Hunter